Cardiovascular diseases (CVD) are diverse disorders affecting the heart and vasculature in
millions of people worldwide. Like other fields, CVD research has benefitted from the deluge …

Ischemic cardiomyopathy (ICM) is the leading cause of heart failure worldwide, yet the
cellular and molecular signature of this disease is largely unclear. Using single-nucleus …

Background Exercise training protects the heart against pathological cardiac remodeling
and confers cardioprotection from heart failure. However, the underlying mechanism is still …

Heart failure (HF) represents a significant global health challenge, characterized by high
morbidity and mortality rates, and imposes considerable burdens on healthcare systems and …

Aims Cardiomyocyte apoptosis is an important factor leading to the occurrence and
development of heart failure (HF), which is associated with high mortality of patients with …

Heart failure with preserved ejection fraction (HFpEF) represents a global health challenge,
with limited therapies proven to enhance patient outcomes. This makes the elucidation of …

The identification of novel drug targets is needed to improve the outcomes of heart failure
(HF). G-protein-coupled receptors (GPCRs) represent the largest family of targets for already …

Background Dilated cardiomyopathy (DCM) is a severe manifestation or intermediate stage
of cardiovascular disease progression with a significantly poor prognosis. Based on a …

Aims Dilated cardiomyopathy (DCM) remains among the most refractory heart diseases
because of its complicated pathogenesis, and the key molecules that cause it remain …

(1) Background: There are few diagnostic and therapeutic targets for myocardial remodeling
in the salvageable non-infarcted myocardium.(2) Methods: Hub genes were identified …